The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

The UK's NICE now recommends the NHS use of Pfizer's daily prostate cancer pill, Talzenna alongside hormone therapy Xtandi.

Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for ...

Speaking at the World Economic Forum in Davos, Donald Trump said tariffs helped fix the long-time drug pricing scam in the US ...

AstraZeneca has agreed to buy AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

Staying ahead of pharma supply challenges rests on anticipatory pillars and does not require reinventing the wheel, says ...

Novartis has announced that the FDA has granted a breakthrough therapy designation to ianalumab, a treatment for Sjögren’s ...

Regene Therapeutics has received RMAT designation from the US FDA for its lead product, NouvNeu001, aimed at treating PD.

As more drugs go subcutaneous, CEO of Phillips Medisize, Tony Bedford, believes that high-dose biologics will become a prevalent choice for drugmakers.

GSK's RAPT Therapeutics acquisition will strengthen the former's immunology pipeline – specifically its offerings for food ...

Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...